HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that it has reached an agreement with Quratis Inc., a Korean biotech company, to co-develop HDT’s revolutionary COVID-19 vaccine (a next-generation mRNA vaccine) for distribution in South Korea and neighboring countries.
HDT already has a partnership with Gennova Biopharmaceuticals in India, and it hopes to announce similar agreements in China and Brazil in the near future.
To deliver immune-stimulating RNA fragments to targeted cells, HDT Bio’s COVID-19 vaccine uses a patented Lipid InOrganic Nanoparticle (LIONTM) formulation. The vaccine, which is currently undergoing clinical trials to determine its safety and efficacy, differs from current mRNA vaccines in two ways.
The RNA payload, for starters, is designed to amplify itself inside the body. As a result, the vaccine activates the immune system at a considerably lower dose than current vaccinations, improving safety and lowering production costs. Second, the HDT LION formulation technology makes manufacturing easier and improves product stability.
In mid-July, Quratis received IND approval from the Ministry of Food and Drug Safety for a Phase I clinical trial of a COVID-19 vaccine, and it is expected to start testing QTP104 in Phase 1 clinical trial soon.
Quratis and Korea have a rare opportunity to battle COVID-19 with the world’s most advanced mRNA vaccine technology, not only in Korea but also in other countries in the area, to help put an end to this horrific epidemic, thanks to their partnership with HDT Bio.
HDT Bio is a biopharmaceutical firm established in Seattle that focuses on bringing immunotherapies to people all around the world, including those in underserved areas. Quratis is a biotech company founded in 2016 that uses advanced adjuvant and antigen discovery technology to develop vaccines for tuberculosis and other infectious diseases. Peptide nucleic acid-based antimicrobial medicines, which are being developed to treat multidrug-resistant tuberculosis, Staphylococcus aureus infections, and cancer, are also part of its technology.